Corpus overview


Overview

MeSH Disease

Human Phenotype

Diarrhea (11)

Fever (7)

Cough (7)

Abdominal pain (6)

Fatigue (6)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 11
    records per page




    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Digestive Manifestations in Patients Hospitalized with COVID-19

    Authors: B. Joseph Elmunzer; Rebecca L. Spitzer; Lydia D. Foster; Ambreen A. Merchant; Eric F. Howard; Vaishali A. Patel; Mary K. West; Emad Qayad; Rosemary Nustas; Ali Zakaria; Marc S. Piper; Jason R. Taylor; Lujain Jaza; Nauzer Forbes; Millie Chau; Luis F. Lara; Georgios I. Papachristou; Michael L. Volk; Liam G. Hilson; Selena Zhou; Vladimir M. Kushnir; Alexandria M. Lenyo; Caroline G. McLeod; Sunil Amin; Gabriela N. Kuftinec; Dhiraj Yadav; Charlie Fox; Jennifer M. Kolb; Swati Pawa; Rishi Pawa; Andrew Canakis; Christopher Huang; Laith H. Jamil; Andrew M. Aneese; Benita K. Glamour; Zachary L. Smith; Katherine A. Hanley; Jordan Wood; Harsh K. Patel; Janak N. Shah; Emil Agarunov; Amrita Sethi; Evan L. Fogel; Gail McNulty; Abdul Haseeb; Judy A. Trieu; Rebekah E. Dixon; Jeong Yun Yang; Robin B. Mendelsohn; Delia Calo; Olga C. Aroniadis; Joseph F. LaComb; James M. Scheiman; Bryan G. Sauer; Duyen T. Dang; Cyrus R. Piraka; Eric D. Shah; Heiko Pohl; William M. Tierney; Stephanie Mitchell; Ashwinee Condon; Adrienne Lenhart; Kulwinder S. Dua; Vikram S. Kanagala; Ayesha Kamal; Vikesh K. Singh; Maria Ines Pinto-Sanchez; Joy M. Hutchinson; Richard S. Kwon; Sheryl J. Korsnes; Harminder Singh; Zahra Solati; Amar R. Deshpande; Don C. Rockey; Teldon B. Alford; Valerie Durkalski; Field F. Willingham; Patrick S. Yachimski; Darwin L. Conwell; Evan Mosier; Mohamed Azab; Anish Patel; James Buxbaum; Sachin Wani; Amitabh Chak; Amy E. Hosmer; Rajesh N. Keswani; Christopher J. DiMaio; Michael S. Bronze; Raman Muthusamy; Marcia I. Canto; V. Mihajlo Gjeorgjievski; Zaid Imam; Fadi Odish; Ahmed I. Edhi; Molly Orosey; Abhinav Tiwari; Soumil Patwardhan; Nicholas G. Brown; Anish A. Patel; Collins O. Ordiah; Ian P. Sloan; Lilian Cruz; Casey L. Koza; Uchechi Okafor; Thomas Hollander; Nancy Furey; Olga Reykhart; Natalia H. Zbib; John A. Damianos; James Esteban; Nick Hajidiacos; Melissa Saul; Melanie Mays; Gulsum Anderson; Kelley Wood; Laura Mathews; Galina Diakova; Molly Caisse; Lauren Wakefield; Haley Nitchie

    doi:10.1101/2020.07.07.20143024 Date: 2020-07-09 Source: medRxiv

    Background: The prevalence SERO and significance of digestive manifestations in COVID-19 remain uncertain. Methods: Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset TRANS until discharge or death MESHD were manually abstracted from electronic health records to characterize the prevalence SERO, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. Results: A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea HP diarrhea MESHD (34%), nausea HP nausea MESHD (27%), vomiting HP vomiting MESHD (16%), and abdominal pain HP abdominal pain MESHD (11%). In 74% of cases, gastrointestinal symptoms MESHD were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death MESHD. Conclusions: Among patients hospitalized with COVID-19, gastrointestinal symptoms MESHD and liver test abnormalities MESHD were common but the majority were mild and their presence was not associated with a more severe clinical course.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-30405/v1 Date: 2020-05-19 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected MESHD patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever HP fever MESHD in 13 (65%) patients, cough HP in 9 (45%), headache HP headache MESHD in 3 (15%), fatigue HP fatigue MESHD in 6 (30%), diarrhea HP diarrhea MESHD in 3 (15%), and abdominal pain HP abdominal pain MESHD in 2 (10%). Six patients (30%) developed shortness of breath MESHD upon admission. The median time from exposure to onset of illness was6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency. The dynamic changes in lymphocyte levels can predict disease status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-23967/v1 Date: 2020-04-21 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected MESHD patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever HP fever MESHD in 13 (65%) patients, cough HP in 9 (45%), headache HP headache MESHD in 3 (15%), fatigue HP fatigue MESHD in 6 (30%), diarrhea HP diarrhea MESHD in 3 (15%), and abdominal pain HP abdominal pain MESHD in 2 (10%). Six patients (30%) developed shortness of breath MESHD upon admission. The median time from exposure to onset of illness was 6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency. The dynamic changes in lymphocyte levels can predict disease status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    Neurological Complications of Pandemic COVID-19: What Have We Got So Far?

    Authors: Isabelle Pastor Bandeira; Marco Antônio Machado Schlindwein; Leticia Caroline Breis; Jean Pierre Schatzmann Peron; Marcus Vinicius Magno Gonçalves

    id:10.20944/preprints202004.0304.v1 Date: 2020-04-17 Source: Preprints.org

    The recently emerged coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS- CoV-2) is the newest threat to human health. It has already infected more than half a million people worldwide, leading to a lot of deaths. Although it causes mild flu-like disease MESHD in most patients, lethality may increase to more than 20% in elderly TRANS subjects, especially those with comorbidities, like hypertension HP hypertension MESHD, diabetes MESHD or lung and cardiac disease MESHD, and the mechanisms are still elusive. Common symptoms at the onset TRANS of illness are fever HP fever MESHD, cough HP cough MESHD, myalgia HP myalgia MESHD or fatigue HP fatigue MESHD, headache HP headache MESHD, and diarrhea HP diarrhea MESHD or constipation HP. Interestingly, respiratory viruses have also placed themselves as relevant agents for CNS pathologies. Here we discuss several CNS related features, referred by several patients, especially at the beginning of the disease. Thus, we also discuss the possibility by which SARS-CoV-2 may affect the olfactive system of patients, either directly or indirectly.

    Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

    Authors: Wei Tang; Zhujun Cao; Mingfeng Han; Zhengyan Wang; Junwen Chen; Wenjin Sun; Yaojie Wu; Wei Xiao; Shengyong Liu; Erzhen Chen; Wei Chen; Xiongbiao Wang; Jiuyong Yang; Jun Lin; Qingxia Zhao; Youqin Yan; Zhibin Xie; Dan Li; Yaofeng Yang; Leshan Liu; Jieming Qu; Guang Ning; Guochao Shi; Qing Xie

    doi:10.1101/2020.04.10.20060558 Date: 2020-04-14 Source: medRxiv

    Abstract Objectives To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard-of-care (SOC) compared with SOC alone in adult TRANS patients with COVID-19. Design Multicenter, open-label, randomized controlled trial. Setting 16 government-designated COVID-19 treatment centers in China through 11 to 29 in February 2020. Participants 150 patients hospitalized with laboratory-confirmed COVID-19 were included in the intention to treat analysis. 75 patients were assigned to HCQ plus SOC and 75 to SOC alone. Interventions HCQ was administrated with a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days (total treatment duration: 2 or 3 weeks for mild/moderate or severe patients, respectively). Main outcome measures The primary outcome was whether participants had a negative conversion of SARS-CoV-2 by 28 days, and was analyzed according to the intention-to-treat principle. Adverse events were analyzed in the safety population in which HCQ recipients were participants who actually received at least one dose of HCQ and HCQ non-recipients were those actually managed with SOC alone. Results Among 150 patients, 148 were with mild to moderate disease and 2 were with severe disease. The mean days ({+/-}standard deviation, min to max) from symptoms onset TRANS to randomization was 16.6 ({+/-}10.5 days, 3 to 41 days). The negative conversion probability by 28 days in SOC plus HCQ group was 85.4% (95% confidence interval (CI) 73.8% to 93.8%), similar to that in the SOC group 81.3% (95%CI 71.2% to 89.6%). Between-group difference was 4.1% (95%CI -10.3% to 18.5%). In the safety population, adverse events were recorded in 7 (8.8%) HCQ non-recipients (N=80) and in 21 (30%) HCQ recipients (N=70). The most common adverse event in the HCQ recipients was diarrhea HP diarrhea MESHD, reported in 7 (10%) patients. Two HCQ recipients reported serious adverse events. Conclusions The administration of HCQ did not result in a significantly higher negative conversion probability than SOC alone in patients mainly hospitalized with persistent mild to moderate COVID-19. Adverse events were higher in HCQ recipients than in HCQ non-recipients. Trial registration ChiCTR2000029868

    Patient with COVID-19 who has no specific onset symptoms TRANS and progresses rapidly to death: a case report

    Authors: Shuaipan Zhang; Lei Fang; Wei Cheng; Chao Zhan; Xiaoming Fang

    doi:10.21203/rs.3.rs-22073/v1 Date: 2020-04-08 Source: ResearchSquare

    BackgroundSince its outbreak, COVID-19 has continued to spread rapidly more than 3 months, which constituted a public health emergence worldwide.The onset symptoms TRANS of patients with COVID-19 are not specific, especially in non-respiratory symptoms, it is easy to be ignored, which can cause widespread infection MESHD. For critically ill MESHD patients, glucocorticoids are used for anti-inflammatory treatment. However, after the application cycle recommended by the guidelines, the deterioration of the patient's condition and treatment to suppress cytokine storms is more critical.Case presentationA previous patient was admitted to the hospital due to abdominal pain HP abdominal pain MESHD and diarrhea HP diarrhea MESHD, and accidentally was confirmed with positive SARS-CoV-2. The patient progressed rapidly from mild to severe within 2 days of admission. With timely anti-viral and anti-inflammatory drugs and early ventilator respiratory support, the patient's condition improved temporarily, and subsequently accompanied by a decrease in glucocorticoids, the patient's condition worsened and eventually died. Her family members TRANS were also hospitalized due to close contact TRANS.ConclusionThis case highlights that even if glucocorticoids are discontinued in accordance with the guidelines, deterioration of the patient's condition is inevitable attribute to the cytokine storms. And related Chinese and western medicines that suppress cytokine storms should be applied in time. In addition, more systematic epidemiological surveillance and stool tests are necessary due to potential lethal risk and route of transmission TRANS.

    Digestive Involvement in SARS-CoV-2 Infection MESHD: A Retrospective Multi-center Study

    Authors: Haitao Shang; Chao Huang; Yuhua Chen; Shengyan Zhang; Pengcheng Yang; Gaichao Hong; Lei Zhang; Xiaohua Hou

    doi:10.21203/rs.3.rs-21375/v1 Date: 2020-04-04 Source: ResearchSquare

    BackgroundCoronavirus disease 2019 (COVID-19) is an emerged infection MESHD raised wide concerns for the pneumonia HP pneumonia MESHD and respiratory manifestations. Also, digestive complications are frequently observed in COVID-19 patients but the significance remains undetermined.MethodsA retrospective analysis of alimentary symptoms, liver dysfunctions MESHD and other clinical parameters of 514 hospitalized COVID-19 patients (282 mild, 162 severe and 70 critical cases) admitted to the 3 designated medical units of Wuhan Union Hospital from Jan 20 to Feb 29, 2020 was performed.Results1) A series of alimentary symptoms, including poor appetite HP(50.2%), diarrhea HP diarrhea MESHD(25.5%), nausea HP nausea MESHD(16.3%), vomit HP vomit MESHD(11.9%) and abdominal pain HP abdominal pain MESHD(3.3%), presented in COVID-19 patients.2) Diarrhea HP Diarrhea MESHD was common gastrointestinal symptom with higher morbidity in the severe and critical patients (32.1% and 27.1% respectively), and 13.2% patients developed diarrhea HP diarrhea MESHD in the first 3 days after onset of symptoms TRANS. Those with diarrhea HP diarrhea MESHD were reported more apparent systemic inflammation MESHD and liver injury MESHD in severe and critical cases compared with patients without diarrhea HP diarrhea MESHD.3) Notably, 31 patients (6.03%) presented with diarrhea HP diarrhea MESHD in the absence of respiratory symptoms. These patients were observed less systemic inflammatory activity relative to diarrhea HP diarrhea MESHD patients combined with respiratory symptoms.4) Also, liver injury MESHD was high incident in COVID-19 patients with increased alanine aminotransferase (43.3%), aspartate transaminase (36.7%) and decreased albumin (80.9%), but less increased total bilirubin HP (10.9%) and direct bilirubin(14.2%), which were more serious in the severe to critical patients.ConclusionsOur data favored in the process of novel SARS-CoV-2 infection MESHD. There may be a “gut-type” in the clinical prevention and management that differ from the “lung-type” in COVID-19 sufferers.

    Clinical characteristics of 57 patients infected with COVID-19 in Baodi area of Tianjin, China

    Authors: Yingchao Zhang; Zhentao Lin; Lijing Wang; Shuxiang Shan

    doi:10.21203/rs.3.rs-19003/v1 Date: 2020-03-24 Source: ResearchSquare

    BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has been spreading worldwide.ObjectiveTo study the clinical characteristics of COVID-19, we included 57 real-time RT-PCR confirmed patients in Baodi area of Tianjin, China, admitted to hospital from 31 January 2020 and 22 February 2020.MethodsEpidemiological, demographic, clinical, and radiological features and laboratory data were analyzed. Patients were confirmed by real-time RT-PCR with pharyngeal swab and/or sputum samples. Some patients that presented positive results with sputum samples yielded negative results with multiple swab tests, suggesting sputum samples RT-PCR tests may be a more reliable means of positively diagnosing infected individuals.ResultsOf the 57 patients studied, three were mild and 54 were moderate in severity. None of the patients infected traveled TRANS to Wuhan indicating all studied cases were infected by human to human transmission TRANS. The most common symptoms at onset TRANS of illness were included fever HP fever MESHD (86%), cough HP (29.8%), myalgia HP myalgia MESHD or fatigue HP fatigue MESHD (14%), chest tightness HP chest tightness MESHD (5.3%), sore throat (5.3%), and diarrhea HP diarrhea MESHD (5.3%).ConclusionCompared with patients of COVID-19 in Wuhan, the symptoms of patients in Baodi area of Tianjin province are relatively mild.

    Clinical and CT imaging characteristics of COVID-19 cases in Wenzhou city: A retrospective analysis

    Authors: Li-ping Fu; Yuan-tong Gao; Ke Zhou; Min Luo; Peng-Cheng Ma; Fa-Huan Song; Yong-chou Li

    doi:10.21203/rs.3.rs-18696/v1 Date: 2020-03-20 Source: ResearchSquare

    Background: In December 2019, Wuhan witnessed the outbreak of an “unexplained pneumonia MESHD” caused by a novel coronavirus strain infection MESHD and was dubbed the COVID-19 by the WHO. The disease quickly spread to China. This study aimed to investigate the disease’s evolving epidemiological history, as well as analyze the clinical and CT imaging characteristics, treatment regimens, and patients’ prognosis. Methods: This was a retrospective study whose cases were 64 patients with a confirmed diagnosis of COVID-19. The clinical data were obtained from patients who were admitted to the isolation ward from 21 January 2020 to 19 February 2020. Results: 60 out of 64 patients had a definitive history of exposure to people who had traveled TRANS from Wuhan City. The median time from onset of symptoms TRANS to first hospital admission was 3.9±1.9 days. The initial symptoms included fever HP fever MESHD (46/64), dry cough MESHD cough HP (38/64), fatigue HP fatigue MESHD or myalgia HP myalgia MESHD (23/64), sore throat (10/64), diarrhea HP diarrhea MESHD (3/64) along with late- onset symptoms TRANS like chest pains HP chest pains MESHD (2/64) and headaches HP headaches MESHD (2/64). The majority of the patients (43/64) had normal white blood SERO cell counts while 29.7 % (19/64) had leukopenia HP leukopenia MESHD. Only two patients (3.1 %) presented with leukocytosis HP leukocytosis MESHD. 58 of the 64patients had abnormal radiological findings on chest CTs. The first chest CTs (within 2 days) was more sensitive in detecting COVID-19 infection MESHD (85.9 %) compared to the initial RT-PCR (56.3 %; p<0.01). The CTs showed lesions in multiple lung lobes in three-quarters of the patients while 15.6 % had lesions localized to one lobe. Most of the lesions were typically dense with ground-glass opacity co-existing with consolidation or cord-like shadows. Most of these patients (50/64) have recovered and got discharged giving a mean length of hospital stay of 13.5±4.8 days. Our hospital unit has not reported any COVID-19 related death so far. Conclusions: Early intervention in COVID-19 disease improves patients’ prognosis. Our data demonstrate the superiority of early radiological tests ahead of RT-PCR. The initial and dynamic CT changes in COVID-19 patients along with other clinical data shared above can better guide clinical decision making.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.